


CLAIMS

1. A compound represented by Formula I:



- 5 or a pharmaceutically acceptable salts thereof, wherein:

R^1 is selected from the group consisting of:

- 10 a) $C(O)R^9$, wherein R^9 is selected from C(1-18) substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl; and
- b) $C(O)-(CH_2)_n-(C(O))_p-(OCH_2CH_2)_mOR^{10}$, wherein $n=0-6$, $p=0-1$, $m=0-22$, and R^{10} is H, substituted or unsubstituted C(1-6) alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;
- 15 c) $C(O)-(CHR^{11})_n-NR^{12}R^{13}$, wherein $n=1-5$, R^{11} is selected from the group consisting of hydrogen, substituted or unsubstituted C(1-8) alkyl, substituted or unsubstituted C(1-8) aralkyl, substituted or unsubstituted C(1-8) aryl, substituted or unsubstituted C(1-8) heteroaryl, and R^{12} and R^{13} are individually selected from the group consisting of hydrogen, substituted or unsubstituted C(1-8) alkyl, substituted or unsubstituted C(1-8) aralkyl,
- 20 substituted or unsubstituted C(1-8) aryl, substituted or unsubstituted C(1-8) heteroaryl, substituted or unsubstituted C(1-8) alkylcarbonyl, substituted or unsubstituted C(1-8) arylcarbonyl, substituted or unsubstituted C(1-8) heteroarylcarbonyl, or wherein R^{12} and R^{13} are combined to form members of a 5 to 7 membered substituted or unsubstituted heterocyclic ring system;

25

R^2 is H

R^5 is selected from the group consisting of H, methyl, and substituted or unsubstituted benzyl,


30

R^6 is selected from the group consisting of


(i) fluoro C(1-6)-alkyl, substituted and unsubstituted C(6-16)-aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted biphenyl, substituted and unsubstituted diphenyl ether, substituted and unsubstituted coumarinyl, and adamantyl;

wherein adjacent carbons in ring systems of the aryl or heteroaryl R^5 substituents or adjacent carbons in ring systems of the aryl, heteroaryl, biphenyl, diphenyl ether, or coumarinyl R^6 substituents may together be substituted by a fused cycloalkyl or heterocycloalkyl ring, which cycloalkyl or heterocycloalkyl ring may be further substituted by one or more an alkyl groups, or two alkyl groups joined to form a ring;

(ii)



(iii)



wherein


X is represented by a bond, O or $S(O)_n$, wherein $n=0, 1$, or 2 , and is attached to ring A at the 2, 3, or 4 position;

R^{23} on ring A is selected from the group consisting of H, halogen, C(1-8)alkyl, C(1-8) alkoxy and represents up to 4 substitutions;

R^{24} through R^{28} of ring B is independently selected from the group consisting of H, halogen, C(1-8) alkyl, C(1-8) fluoroalkyl, C(1-8) alkoxy,

wherein any two adjacent R groups may be combined to form members of a fused aryl, substituted aryl, heteroaryl, or substituted heteroaryl, ring system; and

(iv):



5 wherein

X is represented by a bond, O or S(O)_n, wherein n=0, 1, or 2;

R²³ on ring A is selected from the group consisting of H, halogen, C(1-8) alkyl, C(1-8) alkoxy and represents up to 4 substitutions;

10 the heteroaryl ring systems of ring A and B contain at least one heteroatom and are substituted or unsubstituted;

R²⁴ through R²⁸ of ring B is independently selected from the group consisting of H, halogen, C(1-8) alkyl, C(1-8) fluoroalkyl, C(1-8) alkoxy; and wherein any two adjacent R groups may be combined to form members of a fused aryl, substituted aryl, heteroaryl, or substituted heteroaryl, ring system.

15

2. A compound according to claim 1, wherein R¹ is C(O)R⁹, wherein R⁹ is C(2-4)alkyl.

20

3. A compound according to claim 1, wherein R¹ is C(O)R⁹, wherein R⁹ is C(5-18)alkyl.

4. A compound according to claim 1, wherein R¹ is C(O)-(CHR¹¹)_n-NR¹²R¹³.

5. A compound according to claim 1, wherein R^1 is $C(O)CH_2CH_2-(-O-CH_2CH_2-)_n-OR^{10}$, wherein $n=1-6$ and R^{10} is H or CH_3 .

6. A compound according to claim 1, wherein R^1 is $C(O)-(CH_2)_n-C(O)-(OCH_2CH_2)_mOH$, wherein $n=2-5$ and $m=1-22$.

7. A compound according to claim 1, wherein R^1 is $C(O)-(CH_2CH_2)_n-(O)OR^{10}$, wherein $n=1-8$ and R^{10} is selected from hydrogen, C(1-6) substituted or unsubstituted alkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.

8. A compound according to claim 1, wherein R^1 is $C(O)OR^{10}$, wherein R^{10} is H or CH_3 .

9. A compound according to claim 1, wherein R^1 is $C(O)CH_2CH_2CO_2H$.

10. A compound according to any one of claims 1 to 9, wherein the substituents are selected from the group consisting of:

1) H, halogen, nitro, cyano, C(1-8) alkyl, C(1-8) fluoroalkyl, aralkyl, aryl, heteroaryl, C(1-8) alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, azide, $B(OH)_2$, and adamantyl;

2) XR^{19} wherein $X=O$ or S and R^{19} is defined as a C(1-8) alkyl, hydroxyl, C(1-4) alkoxy, fluoroalkyl, aryl, heteroaryl, lower alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, lower alkylaminocarbonyl, and arylaminocarbonyl; and

3) $NR^{14}R^{15}$ wherein R^{14} and R^{15} are independently defined as C(1-8) alkyl, or wherein R^{14} and R^{15} are joined to form an alkyl or heteroalkyl ring system;

wherein said C(1-8) alkyl, C(1-8) fluoroalkyl, aralkyl, aryl, heteroaryl, C(1-8) alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, and C(1-4) alkoxy may be further substituted, by the substituents 1-3.

11. Compounds 15 through 51 and compound 150.

12. The compound of any one of claims 1 to 11, in the form of a salt, encapsulated in an encapsulating agent.
- 5 13. The compound according to claim 12, wherein the encapsulating agent is a cyclodextran.
14. The compound according to claims 12, wherein the encapsulating agent is hydroxypropylcyclodextran (HPCD).
- 10 15. The compound according to claim 12, 13, or 14, wherein the salt is a salt selected from the group consisting of an ethanolamine salt, a dimethylaminoethanol salt, and a 4-aminopyridine salt.
- 15 16. The compound according to claim 12, 13, or 14, wherein the salt is a sodium salt.
17. Use of a compound according to any one of claims 1 to 16, for the treatment of a neurodegenerative condition.
- 20 18. Use of a compound according to claim 17, for inducing axonal growth and/or repair.
19. Use of a compound according to claim 17, for inducing altering signal transduction.
- 25 20. Use according to any one of claims 17 to 19, wherein the neurodegenerative condition is selected from the group consisting of Alzheimer's, Huntington's, Parkinson's, muscular dystrophy, diabetes, HIV, an ischemic insult, retinal ganglion loss following acute ocular stroke or glaucoma, a neurodegenerative condition resulting from a viral infection, and a neuropathy resulting from the use of chemo-therapeutic agents used in
- 30 the treatment of HIV.

21. Use according to any one of claims claim 17 to 19, wherein the neurodegenerative condition is a degenerative disease of the eye.


22. Use of a compound according to any one of claims 1 to 16, for the treatment of a proliferative condition.

23. Use according to claim 22, wherein the proliferative condition is cancer.

24. Use according to claim 23, wherein said cancer is selected from the group consisting of prostate, colon, neuroblastoma, medulloblastoma, and breast cancer.

25. Use according to any one of claims 17 to 24, wherein the compound is used with other compounds known to the art, for the treatment of the condition.

26. A pharmaceutically acceptable salt of a compound represented by Formula I,



encapsulated in an encapsulating agent, wherein:

R¹ is H or C(1-4) alkyl;

R² is H


R⁵ is selected from the group consisting of H, methyl, substituted or unsubstituted benzyl;

R⁶ is selected from the group consisting of

(i) fluoro C(1-6)-alkyl, substituted and unsubstituted C(6-16)-aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted biphenyl, substituted and unsubstituted diphenyl ether, substituted and unsubstituted coumarinyl, and adamantyl;


wherein adjacent carbons in ring systems of the aryl or heteroaryl R^5 substituents or adjacent carbons in ring systems of the aryl, heteroaryl, biphenyl, diphenyl ether, or coumarinyl R^6 substituents may together be substituted by a fused cycloalkyl or heterocycloalkyl ring, which cycloalkyl or heterocycloalkyl ring may be further substituted by one or more an alkyl groups, or two alkyl groups joined to form a ring;

(ii)



10

(iii)



wherein


X is represented by a bond, O or $S(O)_n$, wherein $n=0, 1$, or 2 , and is attached to ring A at the 2, 3, or 4 position;

R^{23} on ring A is selected from the group consisting of H, halogen, C(1-8)alkyl, C(1-8) alkoxy and represents up to 4 substitutions;

R^{24} through R^{28} of ring B is independently selected from the group consisting of H, halogen, C(1-8) alkyl, C(1-8) fluoroalkyl, C(1-8) alkoxy,

wherein any two adjacent R groups may be combined to form members of a fused aryl, substituted aryl, heteroaryl, or substituted heteroaryl, ring system; and

(iv):



wherein

X is represented by a bond, O or S(O)_n, wherein n=0, 1, or 2;

R²³ on ring A is selected from the group consisting of H, halogen, C(1-8) alkyl, C(1-8) alkoxy and represents up to 4 substitutions;

the heteroaryl ring systems of ring A and B contain at least one heteroatom and are substituted or unsubstituted;

R²⁴ through R²⁸ of ring B is independently selected from the group consisting of H, halogen, C(1-8) alkyl, C(1-8) fluoroalkyl, C(1-8) alkoxy; and wherein any two adjacent R groups may be combined to form members of a fused aryl, substituted aryl, heteroaryl, or substituted heteroaryl, ring system.

27. The compound according to claim 26, wherein the encapsulating agent is a cyclodextran.

28. The compound according to claims 26, wherein the encapsulating agent is hydroxypropylcyclodextran (HPCD).


29. Use of the compound according to any one of claims 26 to 28, for the treatment of a proliferative condition.

30. Use according to claim 29, wherein the proliferative condition is cancer.

31. Use according to claim 30, wherein said cancer is selected from the group consisting of prostate, colon, neuroblastoma, medulloblastoma, and breast cancer.

32. Use according to any one of claims 29 to 31, wherein the compound is used with
5 other compounds known in the art, for the treatment of the proliferative condition.

33. Use of a compound represented by Formula I,



10 or a pharmaceutically acceptable salt thereof, for the treatment of a proliferative condition, wherein:

R¹ is H or C(1-4) alkyl;

R² is H

15

R⁵ is selected from the group consisting of H, methyl, substituted or unsubstituted benzyl;

R⁶ is selected from the group consisting of


20

(i) fluoro C(1-6)-alkyl, substituted and unsubstituted C(6-16)-aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted biphenyl, substituted and unsubstituted diphenyl ether, substituted and unsubstituted coumarinyl, and adamantyl;


wherein adjacent carbons in ring systems of the aryl or heteroaryl R⁵ substituents or adjacent carbons in ring systems of the aryl, heteroaryl, biphenyl, diphenyl ether, or
25 coumarinyl R⁶ substituents may together be substituted by a fused cycloalkyl or heterocycloalkyl ring, which cycloalkyl or heterocycloalkyl ring may be further substituted by one or more an alkyl groups, or two alkyl groups joined to form a ring;

(ii)

65



(iii)



5

wherein

X is represented by a bond, O or S(O)_n, wherein n=0, 1, or 2, and is attached to ring A at the 2, 3, or 4 position;

R²³ on ring A is selected from the group consisting of H, halogen, C(1-8)alkyl, C(1-8) alkoxy and represents up to 4 substitutions;



10

R²⁴ through R²⁸ of ring B is independently selected from the group consisting of H, halogen, C(1-8) alkyl, C(1-8) fluoroalkyl, C(1-8) alkoxy,

wherein any two adjacent R groups may be combined to form members of a fused aryl, substituted aryl, heteroaryl, or substituted heteroaryl, ring system; and

15

(iv):



wherein

X is represented by a bond, O or S(O)_n, wherein n=0, 1, or 2;

R²³ on ring A is selected from the group consisting of H, halogen, C(1-8) alkyl,

5 C(1-8) alkoxy and represents up to 4 substitutions;

the heteroaryl ring systems of ring A and B contain at least one heteroatom and are substituted or unsubstituted;

R²⁴ through R²⁸ of ring B is independently selected from the group consisting of H, halogen, C(1-8) alkyl, C(1-8) fluoroalkyl, C(1-8) alkoxy; and

10 wherein any two adjacent R groups may be combined to form members of a fused aryl, substituted aryl, heteroaryl, or substituted heteroaryl, ring system.


34. Use according to claim 33, wherein the proliferative condition is cancer.

15 35. Use according to claim 34, wherein said cancer is selected from the group consisting of prostate, colon, neuroblastoma, medulloblastoma, and breast cancer.

36. Use according to any one of claims 33 to 35, wherein the compound is used with other compounds known in the art, for the treatment of the proliferative condition.

20

37. A compound according to any one of claims 2 to 9 where R¹ is defined as in claims 2 to 9 and R²=R⁵=H and R⁶ is chosen from the following:



38. Use of a compound according to Claim 37 for the treatment of a neurodegenerative disease or a proliferative diseases.
- 5 39. Use of a compound according to Claim 38 wherein said proliferative disease is cancer.